SeaStar Medical to Sponsor the Critical Care Time Podcast Series Covering Vital Medical Issues for Healthcare Professionals Who Care for Critically Ill Patients

DENVER, June 30, 2023 (GLOBE NEWSWIRE) — SeaStar Medical Holding Corporation (Nasdaq: ICU), a medical device company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs, announces its primary sponsorship of the first season of the Critical Care Time podcast series. These 24 weekly podcasts will delve into vital medical issues facing healthcare professionals who care for critically ill patients. The first podcast in the series, “Undifferentiated Shock: I,” will broadcast during the week of July 3^rd and will be available here.

Critical Care Time Podcast

“We are excited to partner with Critical Care Time as the primary sponsor of its inaugural season. These podcasts will share insightful discussions of issues faced by physicians who care for the critically ill, whether the patient is in an intensive care unit, emergency department, operating room or ambulance,” said Kevin Chung, MD, Chief Medical Officer of SeaStar Medical. “We are impressed by the Critical Care Time team of leading physicians and are confident this podcast series will be a valuable educational resource for critical care practitioners in their fight to save lives.

“Our sponsorship allows SeaStar Medical to connect with the healthcare professionals we are working to support with our novel, patented Selective Cytopheretic Device. The SCD is our cell-directed extracorporeal therapy that has the potential to save the lives of critically ill patients afflicted with organ-damaging hyperinflammation,” he added.

“We are tremendously grateful for SeaStar Medical’s support in helping us achieve our dream of establishing this podcast,” said Cyrus Askin, MD, podcast co-creator. “We intend to take deep dives into some complex critical care issues including respectful discussions of messy or controversial topics not typically covered by other podcasts. Importantly, our focus will be on telling the human stories behind the clinical practice of medicine. After a year of planning, we are excited to finally go live.”

About the Critical Care Time Podcast
Critical Care Time strives to support all who care for the critically ill patient. Our podcasts will embrace a multi-modality learning environment that combines high-quality audio, video and infographics to enhance the educational experience. The first season of Critical Care Time is expected to include 24 podcasts of approximately 30 minutes each available here. For more information visit www.criticalcaretime.com or visit us on Twitter, Instagram or YouTube.

About SeaStar Medical
SeaStar Medical is a medical technology company that is redefining how extracorporeal therapies can reduce the consequences of excessive inflammation on vital organs. SeaStar Medical’s novel technologies rely on science and innovation to provide life-saving solutions to critically ill patients. The Company is developing and commercializing cell-directed extracorporeal therapies that target the effector cells that drive systemic inflammation, causing direct tissue damage and secreting a range of pro-inflammatory cytokines that initiate and propagate imbalanced immune responses. For more information visit www.seastarmedical.com or visit us on LinkedIn or Twitter.

Forward-Looking Statements
This press release contains certain forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1955. These forward-looking statements include, without limitation, SeaStar Medical’s expectations with respect to the timing of regulatory approval of its products, the expected timing on enrollment, generation of study results, submission of PMA and other corporate milestones, the ability of SCD to treat patients with AKI, and the potential benefits of SCD to treat other diseases. Words such as “believe,” “project,” “expect,” “anticipate,” “estimate,” “intend,” “strategy,” “future,” “opportunity,” “plan,” “may,” “should,” “will,” “would,” “will be,” “will continue,” “will likely result,” and similar expressions are intended to identify such forward-looking statements. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to significant risks and uncertainties that could cause the actual results to differ materially from the expected results. Most of these factors are outside SeaStar Medical’s control and are difficult to predict. Factors that may cause actual future events to differ materially from the expected results include, but are not limited to: (i) the inability to recognize the anticipated benefits of the business combination with LMAO, which may be affected by, among other things, competition and the ability of the post-combination company to grow and manage growth profitability and retain its key employees, (ii) future capital requirements and sources and uses of cash, (iii) the ability to obtain funding or raise capital for its operations and future growth, (iv) the ability to maintain the listing of its securities on Nasdaq, (v) any delays or challenges in obtaining FDA approval Company’s SCD product candidates, (vi) the risk of downturns and the possibility of rapid change in the highly competitive industry in which SeaStar Medical operates, (vii) the risk that SeaStar Medical and its current and future collaborators are unable to successfully develop and commercialize its products or services, or experience significant delays in doing so, including failure to achieve approval of its products by applicable federal and state regulators, (viii) the risk that SeaStar Medical may never achieve or sustain profitability; (ix) the risk that SeaStar Medical may need to raise additional capital to execute its business plan, which may not be available on acceptable terms or at all; (x) the risk that third-parties suppliers and manufacturers are not able to fully and timely meet their obligations, (xi) the risk of product liability or regulatory lawsuits or proceedings relating to SeaStar Medical’s products and services, (xii) the risk that SeaStar Medical is unable to secure or protect its intellectual property, and (xiii) other risks and uncertainties indicated in SeaStar Medical’s Annual Report on Form 10-K, including those under “Risk Factors” section therein, and other filings that have been made or will be made with the SEC. These forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and SeaStar Medical assumes no obligation and does not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise.

Contact:

LHA Investor Relations
Jody Cain
(310) 691-7100
Jcain@lhai.com

# # #